PCN14 COST-EFFECTIVENESS ANALYSIS OF ARANESP® (DARBEPOETIN ALFA) ADMINISTERED ONCE EVERY THREE WEEKS COMPARED TO ONCE EVERY WEEK
نویسندگان
چکیده
منابع مشابه
Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease.
BACKGROUND/AIMS Darbepoetin alfa is an erythropoiesis-stimulating protein that works via the same mechanism and has a threefold longer serum half-life than recombinant human erythropoietin (rHuEPO). The objective of this study was to evaluate extending the dosing interval of darbepoetin alfa to once every other week administration for the treatment of anemia in patients with chronic kidney dise...
متن کاملDarbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-w...
متن کاملDarbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
The objectives of this study were to assess the safety and efficacy of darbepoetin alfa (Aranesp) administered every 2 weeks in anemic patients with solid tumors receiving chemotherapy. This was an open-label, randomized, active-controlled, multicenter dose-finding study evaluating a range of every-2-week darbepoetin alfa doses. The active control arm received epoetin alfa (Epogen, Procrit) at ...
متن کاملDarbepoetin alfa (Aranesp).
BUMC PROCEEDINGS 2002;15:332–335 The Food and Drug Administration (FDA) approved darbepoetin alfa (Aranesp) for treatment of anemia as sociated with chronic renal failure (CRF) in patients on dialysis and patients not on dialysis (1). The manufacturer of the drug also filed an application with the FDA on September 18, 2001, to receive an indication for treatment of anemia in patients with cance...
متن کاملOnce-every-2-weeks and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients.
BACKGROUND Currently, less frequent than once-weekly subcutaneous epoetin administration regimens were shown to be equally effective and safe as once-weekly schedules in stable predialysis and peritoneal dialysis patients. Bioequivalency of once-every-2-weeks and once-weekly subcutaneous administration of the same total dose of epoetin beta for the maintenance phase of anemia treatment in stabl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2005
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)67252-x